Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? (Q35896530)

11 August 2017

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? (English)

1 reference

11 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

I Watermann

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

B Schmitt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

F Stellmacher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

J Müller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

R Gaber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

Ch Kugler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

N Reinmuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

R M Huber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

M Thomas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

P Zabel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

K F Rabe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

D Jonigk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

A Warth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

E Vollmer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

M Reck

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

language of work or name

1 reference

28 July 2015

1 reference

11 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

page(s)

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

15 June 2020

start time

28 July 2015

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

The 7th lung cancer TNM classification and staging system: Review of the changes and implications

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

HOPE-BAL: improved molecular diagnostics by application of a novel technique for fixation and paraffin embedding

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Drug development of MET inhibitors: targeting oncogene addiction and expedience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Met, metastasis, motility and more

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

HOPE-fixation of lung tissue allows retrospective proteome and phosphoproteome studies

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Tissue microarrays from HOPE-fixed specimens allow for enhanced high throughput molecular analyses in paraffin-embedded material.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

HOPE fixation: a novel fixing method and paraffin-embedding technique for human soft tissues.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4517562

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26215852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaisham

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26215852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Crizotinib in ROS1-rearranged non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26215852

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S13000-015-0362-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

15 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json

15 June 2020

PubMed publication ID

26215852

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215852%20AND%20SRC:MED&resulttype=core&format=json